The estimated Net Worth of Jonathan Michael Yingling is at least $10.1 Thousand dollars as of 7 January 2020. Jonathan Yingling owns over 1,742 units of Idera Pharmaceuticals stock worth over $7,034 and over the last 8 years Jonathan sold IDRA stock worth over $3,101.
Jonathan has made over 1 trades of the Idera Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently Jonathan sold 1,742 units of IDRA stock worth $3,101 on 7 January 2020.
The largest trade Jonathan's ever made was selling 1,742 units of Idera Pharmaceuticals stock on 7 January 2020 worth over $3,101. On average, Jonathan trades about 249 units every 0 days since 2017. As of 7 January 2020 Jonathan still owns at least 16,358 units of Idera Pharmaceuticals stock.
You can see the complete history of Jonathan Yingling stock trades at the bottom of the page.
Jonathan's mailing address filed with the SEC is 505 Eagleview Blvd, Exton, PA 19341, USA.
Over the last 17 years, insiders at Idera Pharmaceuticals have traded over $20,746,904 worth of Idera Pharmaceuticals stock and bought 38,459,430 units worth $53,771,070 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp Baker Bro..., and Invest Corp Pillar Pharmace.... On average, Idera Pharmaceuticals executives and independent directors trade stock every 43 days with the average trade being worth of $309,429. The most recent stock trade was executed by John J. Kirby on 17 December 2021, trading 10,000 units of IDRA stock currently worth $6,200.
Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.
Idera Pharmaceuticals executives and other stock owners filed with the SEC include: